restrict the use of Rezulin (troglitazone) for diabetes

April 1999

The FDA will further restrict the use of Rezulin (troglitazone) for diabetes.

There continue to be deaths due to hepatic failure...despite recommendations for more frequent monitoring.

Very few Rezulin patients get regular liver function tests.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote